Understanding inflammation and drug delivery in pulmonary tuberculosis
Cavity and Granuloma Oriented Inflammation and Tissue Pharmacokinetics in Pulmonary Tuberculosis (COOK TB)
This study is looking at how inflammation and damage in the lungs from tuberculosis can make it harder for anti-TB medicines to work, and it aims to find better ways to deliver these drugs to help patients heal more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11015016 on NIH RePORTER |
What this research studies
This research investigates how inflammation and tissue damage in pulmonary tuberculosis (TB) affect the effectiveness of anti-TB drugs. It focuses on the formation of cavitary lesions in the lungs, which can hinder drug penetration and lead to worse health outcomes. By using advanced imaging techniques and analyzing tissue samples, the study aims to map the inflammatory responses and drug distribution in these lesions. The goal is to identify new treatment strategies that can improve drug delivery and reduce lung damage in TB patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary tuberculosis, particularly those exhibiting cavitary lesions in their lungs.
Not a fit: Patients with non-pulmonary forms of tuberculosis or those who do not have cavitary lesions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for pulmonary tuberculosis, potentially reducing mortality and improving patient outcomes.
How similar studies have performed: Previous research has shown promise in understanding drug delivery in TB, but this approach is innovative in its focus on the specific mechanisms of inflammation and drug penetration in cavitary lesions.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Kempker, Russell Ryan — Emory University
- Study coordinator: Kempker, Russell Ryan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.